Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Medicare Rx Bill Offers Juicier Reinsurance Bait; HIAA Bites

Executive Summary

The House Republican Medicare drug benefit bill is wooing plan sponsors with a 35% direct subsidy plus a 30% reinsurance rate for additional costs

You may also be interested in...



White House Opposes Stand-Alone Medicare Rx Benefit – CMS’ Scully

The Bush Administration will resist any Medicare prescription drug legislation that establishes a stand-alone benefit even if administered through private plans, Centers for Medicare & Medicaid Services Administrator Tom Scully said at a National Center for Policy Analysis briefing April 29

White House Opposes Stand-Alone Medicare Rx Benefit – CMS’ Scully

The Bush Administration will resist any Medicare prescription drug legislation that establishes a stand-alone benefit even if administered through private plans, Centers for Medicare & Medicaid Services Administrator Tom Scully said at a National Center for Policy Analysis briefing April 29

Medicare Rx Outlook In 108th Congress: How Much Will Lott Allot To Bill?

The prospects for a Medicare prescription drug benefit in the next Congress hinge on the incoming Senate leadership's ability to negotiate long-standing divisions within the party about how much funding to commit to the program

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel